Ginkgo biloba extract: review of CNS effects.
Study Design
- Тип исследования
- Review
- Популяция
- General healthy population, elderly
- Вмешательство
- Ginkgo biloba extract: review of CNS effects. Ginkgo biloba extract
- Препарат сравнения
- None
- Первичный исход
- CNS effects for brain function maintenance
- Направление эффекта
- Positive
- Риск систематической ошибки
- Unclear
Abstract
The marketing of Ginkgo biloba extract (GBE) products is directed to the healthy, not diseased, population primarily for the promotion and maintenance of optimal brain function, not the treatment or prevention of any specific pathological state. However, recommendations are available for the use of GBE for a myriad of diseases that generally fall into one of three categories--cerebrovascular, peripheral vascular, or mitigation of tissue damage. The evidence for the pharmacological actions of GBE stem from one of three types of investigations--clinical studies in humans, pharmacological trials in animals, and in vitro studies. The purpose of this paper is to review the scientific literature on the central nervous system effects of GBE, with emphasis on the potential mechanisms of action. Limitations of the current scientific literature are highlighted and suggestions for future human and animal research directions are proposed.
Кратко
The purpose of this paper is to review the scientific literature on the central nervous system effects of GBE, with emphasis on the potential mechanisms of action.
Used In Evidence Reviews
Similar Papers
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2020
Isorhamnetin: A review of pharmacological effects.
Archives of physical medicine and rehabilitation · 2000
Ginkgo biloba extract: mechanisms and clinical indications.
The Cochrane database of systematic reviews · 2007
Ginkgo biloba for cognitive impairment and dementia.
JAMA · 2009
Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial.
The Cochrane database of systematic reviews · 2009
Ginkgo biloba for cognitive impairment and dementia.
Clinical pharmacokinetics · 2013